Additionally, NKT cells possess NKR-mediated killing capabilities, which align with the increased expression of NKR ligands, such as CD112, CD155, and MICA/B, observed on blasts and particularly LSPCs in both AML and MDS patients (Fig. 1c–e, j, k). This evidence concerns the gene PVR and acute myeloid leukemia.